Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-006266

Revance Therapeutics, Inc. · RVNC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Lauren P Silvernail
Officer — CFO, CBO & Secretary
Period of report
Jan 26, 2017
Accepted (ET)
Jan 30, 2017 · 9:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Jan 26, 2017A10,000$0.00A40,691D
Common StockF2Jan 28, 2017D1,063$20.00D39,628D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Buy)F3$19.70Jan 26, 2017A60,000A—Jan 25, 2027Common Stock60,00060,000D

Explanation of responses